Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Recruiting · NCT07701161 · Observational (researchers observe without assigning treatment) · Lead sponsor: Neurogen Biomarking LLC
View the official record on ClinicalTrials.gov →What this trial is about
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Who can take part
Age range
40 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
Exclusion criteria
- Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Where it is running
5 locations listed across 3 US states.
- Insigth Hospital and Medical Center Chicago - Chicago, Illinois, United States
- Insight Hospital and Medical Center Dearborn - Dearborn, Michigan, United States
- Insight Institute of Neurology and Neurosurgery - Flint, Michigan, United States
- Memorial Healthcare Hospital - Owosso, Michigan, United States
- Wake Forest Baptist Medical Center - Winston-Salem, North Carolina, United States